Teijin Limited Signs Joint R&D Agreement with Garwood Medical Devices
Electrochemical therapeutic technology BioPrax™ addresses the high failure rate of joint implants due to infection
BUFFALO, NY, UNITED STATES, January 3, 2024 /EINPresswire.com/ — Garwood Medical Devices, a breakthrough New York medtech company, and Teijin Limited, a leading Japanese conglomerate with pharmaceutical and implantable medical device businesses, have announced a joint research and development agreement designed to enable Garwood and Teijin to bring Garwood’s novel infection control technology to Japan. Garwood has developed a unique electrochemical anti-infection technology that has been shown to be effective in treating infections associated with joint and other metallic implants.
